<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-709
Date of Submission: 2025-03-03

This report was submitted by a Other Healthcare Professional from Mathis, Spencer and Peterson Medical Center concerning patient ANON-PX-5953. The subject is an adult other with a significant medical history including coronary artery disease, migraines, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Sertraline administered via the Oral route at a dosage of 391mg, initiated on 2025-01-03 for Major depressive disorder with the course ongoing.

On approximately 2025-02-07, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Anaphylaxis, Vomiting. The Maculopapular Rash was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed culture and advised environmental. The current patient status regarding this symptom is 'Unknown'. The Vomiting was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: News finish back worker me audience receive. The teach study build same thank. Participant improve young whose significant raise. Call contain role animal color change official.</data>
report_id: ADR-2025-709
report_date: '2025-03-03'
patient_details:
  patient_id: ANON-PX-5953
  gender: Other
  relevant_history:
  - coronary artery disease
  - migraines
  - type 2 diabetes
suspected_drugs:
- drug_name: Sertraline
  dosage: 391mg
  route_of_administration: Oral
  start_date: '2025-01-03'
  indication_for_use: Major depressive disorder
adverse_reactions:
- symptom_name: Maculopapular Rash
  onset_date: '2025-02-07'
  severity: Mild
  outcome: Not Recovered
  intervention_required: false
- symptom_name: Anaphylaxis
  onset_date: '2025-02-07'
  severity: Severe
  outcome: Unknown
  intervention_required: true
  intervention_details: Prescribed culture and advised environmental.
- symptom_name: Vomiting
  onset_date: '2025-02-07'
  severity: Life-threatening
  outcome: Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Positive dechallenge
  naranjo_score: 4
reporting_facility: Mathis, Spencer and Peterson Medical Center
reporter_type: Other Healthcare Professional
notes: News finish back worker me audience receive. The teach study build same thank.
  Participant improve young whose significant raise. Call contain role animal color
  change official.
